- Home
- IBG vs BRTX Comparison
IBG vs BRTX Comparison
Compare IBG & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBG | BRTX |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Managed Health Care |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 9.1M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBG | BRTX |
|---|---|---|
| Price | $4.78 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 155.3K | 22.3K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | $3.27 | $0.98 |
| 52 Week High | $49.25 | $2.50 |
Technical Indicators
Market Signals| Indicator | IBG | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.